| UniProt ID | AT1B1_HUMAN | |
|---|---|---|
| UniProt AC | P05026 | |
| Protein Name | Sodium/potassium-transporting ATPase subunit beta-1 | |
| Gene Name | ATP1B1 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 303 | |
| Subcellular Localization |
Cell membrane Single-pass type II membrane protein . Cell membrane, sarcolemma . Colocalizes with OBSCN at the intercalated disk and sarcolemma in cardiomyocytes. Localizes in long striations at the level of Z and M lines. |
|
| Protein Description | This is the non-catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of Na(+) and K(+) ions across the plasma membrane. The beta subunit regulates, through assembly of alpha/beta heterodimers, the number of sodium pumps transported to the plasma membrane.; Involved in cell adhesion and establishing epithelial cell polarity.. | |
| Protein Sequence | MARGKAKEEGSWKKFIWNSEKKEFLGRTGGSWFKILLFYVIFYGCLAGIFIGTIQVMLLTISEFKPTYQDRVAPPGLTQIPQIQKTEISFRPNDPKSYEAYVLNIVRFLEKYKDSAQRDDMIFEDCGDVPSEPKERGDFNHERGERKVCRFKLEWLGNCSGLNDETYGYKEGKPCIIIKLNRVLGFKPKPPKNESLETYPVMKYNPNVLPVQCTGKRDEDKDKVGNVEYFGLGNSPGFPLQYYPYYGKLLQPKYLQPLLAVQFTNLTMDTEIRIECKAYGENIGYSEKDRFQGRFDVKIEVKS | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 11 | Phosphorylation | GKAKEEGSWKKFIWN CCCCCCCCCCCEEEE | 38.71 | 28348404 | |
| 13 | 2-Hydroxyisobutyrylation | AKEEGSWKKFIWNSE CCCCCCCCCEEEECH | 39.23 | - | |
| 13 | Ubiquitination | AKEEGSWKKFIWNSE CCCCCCCCCEEEECH | 39.23 | - | |
| 14 | Ubiquitination | KEEGSWKKFIWNSEK CCCCCCCCEEEECHH | 35.50 | - | |
| 21 | Ubiquitination | KFIWNSEKKEFLGRT CEEEECHHHHHHCCC | 58.38 | - | |
| 85 | Ubiquitination | TQIPQIQKTEISFRP CCCCCCEEEEEEECC | 50.16 | - | |
| 96 | Ubiquitination | SFRPNDPKSYEAYVL EECCCCCCHHHHHHH | 69.41 | - | |
| 96 (in isoform 2) | Ubiquitination | - | 69.41 | - | |
| 97 | Phosphorylation | FRPNDPKSYEAYVLN ECCCCCCHHHHHHHH | 33.33 | 28152594 | |
| 98 | Phosphorylation | RPNDPKSYEAYVLNI CCCCCCHHHHHHHHH | 15.65 | 28152594 | |
| 101 | Phosphorylation | DPKSYEAYVLNIVRF CCCHHHHHHHHHHHH | 8.11 | 22817900 | |
| 113 | 2-Hydroxyisobutyrylation | VRFLEKYKDSAQRDD HHHHHHHHHHHCCCC | 57.16 | - | |
| 113 | Ubiquitination | VRFLEKYKDSAQRDD HHHHHHHHHHHCCCC | 57.16 | - | |
| 118 | Methylation | KYKDSAQRDDMIFED HHHHHHCCCCCEEEC | 41.43 | - | |
| 118 | Dimethylation | KYKDSAQRDDMIFED HHHHHHCCCCCEEEC | 41.43 | - | |
| 121 | Sulfoxidation | DSAQRDDMIFEDCGD HHHCCCCCEEECCCC | 4.41 | 28465586 | |
| 134 | Ubiquitination | GDVPSEPKERGDFNH CCCCCCCHHCCCCCC | 56.86 | - | |
| 147 | Ubiquitination | NHERGERKVCRFKLE CCCCCCCEEEEEEEE | 41.19 | - | |
| 152 | Ubiquitination | ERKVCRFKLEWLGNC CCEEEEEEEEECCCC | 26.58 | - | |
| 158 | N-linked_Glycosylation | FKLEWLGNCSGLNDE EEEEECCCCCCCCCC | 18.01 | 12754519 | |
| 170 | Ubiquitination | NDETYGYKEGKPCII CCCCCCCCCCCEEEE | 56.48 | - | |
| 173 | Ubiquitination | TYGYKEGKPCIIIKL CCCCCCCCEEEEEEE | 37.50 | - | |
| 179 | Ubiquitination | GKPCIIIKLNRVLGF CCEEEEEEECCCCCC | 29.33 | - | |
| 187 | Ubiquitination | LNRVLGFKPKPPKNE ECCCCCCCCCCCCCC | 50.78 | - | |
| 193 | N-linked_Glycosylation | FKPKPPKNESLETYP CCCCCCCCCCCCCCC | 50.27 | 12754519 | |
| 195 | Phosphorylation | PKPPKNESLETYPVM CCCCCCCCCCCCCEE | 40.68 | 30242111 | |
| 198 | Phosphorylation | PKNESLETYPVMKYN CCCCCCCCCCEEECC | 38.12 | 30242111 | |
| 199 | Phosphorylation | KNESLETYPVMKYNP CCCCCCCCCEEECCC | 5.62 | 30242111 | |
| 216 | Ubiquitination | LPVQCTGKRDEDKDK ECEECCCCCCCCCCC | 38.22 | - | |
| 216 | 2-Hydroxyisobutyrylation | LPVQCTGKRDEDKDK ECEECCCCCCCCCCC | 38.22 | - | |
| 221 | Ubiquitination | TGKRDEDKDKVGNVE CCCCCCCCCCCCCEE | 58.35 | - | |
| 223 | Ubiquitination | KRDEDKDKVGNVEYF CCCCCCCCCCCEEEE | 58.75 | - | |
| 229 | Phosphorylation | DKVGNVEYFGLGNSP CCCCCEEEEECCCCC | 9.92 | 29978859 | |
| 235 | Phosphorylation | EYFGLGNSPGFPLQY EEEECCCCCCCCCHH | 25.30 | 29978859 | |
| 242 | Phosphorylation | SPGFPLQYYPYYGKL CCCCCCHHHCCCCEE | 17.68 | 29978859 | |
| 243 | Phosphorylation | PGFPLQYYPYYGKLL CCCCCHHHCCCCEEC | 3.33 | 29978859 | |
| 245 | Phosphorylation | FPLQYYPYYGKLLQP CCCHHHCCCCEECCH | 14.55 | 29978859 | |
| 246 | Phosphorylation | PLQYYPYYGKLLQPK CCHHHCCCCEECCHH | 11.86 | 29978859 | |
| 248 (in isoform 2) | Ubiquitination | - | 29.87 | - | |
| 248 | Ubiquitination | QYYPYYGKLLQPKYL HHHCCCCEECCHHHH | 29.87 | - | |
| 254 | Phosphorylation | GKLLQPKYLQPLLAV CEECCHHHHHHEEEE | 19.77 | - | |
| 265 | N-linked_Glycosylation | LLAVQFTNLTMDTEI EEEEEEECCCCCCEE | 34.50 | 12754519 | |
| 265 | N-linked_Glycosylation | LLAVQFTNLTMDTEI EEEEEEECCCCCCEE | 34.50 | 19522481 | |
| 277 | Ubiquitination | TEIRIECKAYGENIG CEEEEEEEECCCCCC | 31.67 | - | |
| 285 | Phosphorylation | AYGENIGYSEKDRFQ ECCCCCCCCHHHCCC | 15.17 | - | |
| 288 | Ubiquitination | ENIGYSEKDRFQGRF CCCCCCHHHCCCCEE | 48.54 | - | |
| 288 | 2-Hydroxyisobutyrylation | ENIGYSEKDRFQGRF CCCCCCHHHCCCCEE | 48.54 | - | |
| 288 | Acetylation | ENIGYSEKDRFQGRF CCCCCCHHHCCCCEE | 48.54 | 27452117 |
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of AT1B1_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of AT1B1_HUMAN !! | ||||||
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| D00112 | G-Strophanthin (JAN); Ouabain; Ouabain octahydrate | |||||
| D00297 | Digitoxin (JP16/USP/INN); Crystodigin (TN) | |||||
| D00298 | Digoxin (JP16/USP); Lanoxicaps (TN); Lanoxin (TN) | |||||
| D01240 | Deslanoside (JP16/USP/INN); Cedilanid-d (TN) | |||||
| D01379 | Proscillaridin (JAN/USAN/INN); Talusin (TN) | |||||
| D01972 | Lanatoside C (JP16/INN); Digilanogen C (TN) | |||||
| D02587 | Metildigoxin (JP16); Lanirapid (TN) | |||||
| D06881 | Acetyldigitoxin (INN); Acylanid (TN) | |||||
| D07147 | Gitoformate (INN) | |||||
| D07555 | Acetyldigoxin; Cedigossima (TN) | |||||
| D07556 | beta-Acetyldigoxin; Acetyldigoxin beta isomer; Corotal (TN) | |||||
| D09847 | Metildigoxin (INN); Medigoxin (BAN) | |||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| N-linked Glycosylation | |
| Reference | PubMed |
| "Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins."; Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,Schiess R., Aebersold R., Watts J.D.; Nat. Biotechnol. 27:378-386(2009). Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-265, AND MASSSPECTROMETRY. | |
| "Glycoproteomics analysis of human liver tissue by combination ofmultiple enzyme digestion and hydrazide chemistry."; Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; J. Proteome Res. 8:651-661(2009). Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-158; ASN-193 AND ASN-265,AND MASS SPECTROMETRY. | |
| "Identification and quantification of N-linked glycoproteins usinghydrazide chemistry, stable isotope labeling and mass spectrometry."; Zhang H., Li X.-J., Martin D.B., Aebersold R.; Nat. Biotechnol. 21:660-666(2003). Cited for: GLYCOSYLATION AT ASN-158; ASN-193 AND ASN-265. | |